76. Universal Influenza Vaccines
Session: Symposium: Innovations in Influenza Vaccines: Strategic Advances in Improving Immunogenicity
Thursday, October 20, 2011: 4:05 PM
Room: 253ABC


Robert C. Huebner, PhD, HHS/ASPR/BARDA, Washington, DC

Dr. Huebner serves as Acting Director of the Influenza Division in the Biomedical Advancement Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The Influenza Division of BARDA is responsible for preparing the Nation for influenza pandemics and coordinating the production and delivery of medical countermeasures during a pandemic response. Dr. Huebner has been a member of the Influenza Division since May of 2006. He originally joined HHS’ BARDA as a contractor and was named Deputy Director of the Influenza Division in March 2009. Aside from the daily duties as Deputy Director, Dr. Huebner works as senior team member and subject matter expert for cell-based and egg-based pandemic influenza vaccine programs. Dr. Huebner is an experienced biotechnology program manager with over 25 years of research experience with viral and microbiological pathogens, expertise in the vaccine industry, group management, and program management. He previously worked for Sanofi Pasteur as a Manager of Molecular Biology & Microbiology where he supported vaccine development projects in the areas of Lyme disease, influenza and pneumococcal disease. Additionally, Dr. Huebner worked as a Senior Advisor and section manager for Biotechnology at the Midwest Research Institute (Kansas City, MO) where he led the Biotechnology team in supporting government and commercial contract research projects in the areas of vaccine evaluation, pathogen detection and pathogen destruction. Dr. Huebner received his Ph.D. in Molecular Biology and Microbiology from Tufts University (Boston, MA) and his B.S. in Biology from Carnegie Mellon University (Pittsburgh, PA) where he received the Outstanding Undergraduate Research Award for his work on mutants of E. coli DNA polymerase I.



<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.